The Rating & Price Target Process

The previous two chapters covered building and maintaining the model behind a rating. This final chapter covers the rating and price target itself — how it actually changes over time, how sell-side and buy-side research genuinely differ, and the real structural conflicts worth understanding honestly.

Ratings changes — a genuinely significant, deliberate event

Unlike routine estimate revisions (previous chapter), an actual ratings change (Hold to Buy, or Buy to Sell) is a more significant, deliberately considered event — usually reflecting a real, material shift in the analyst's thesis, not just a modest estimate tweak. Because ratings changes are relatively rare and genuinely move markets on their own (especially from a widely-followed analyst at a major firm), they're typically reviewed internally before publication, distinct from the more routine, frequent process of updating estimates and price targets within an unchanged rating.

Price target changes without a ratings change

A price target can move — sometimes significantly — without any change in rating at all: if a stock has run up toward its existing target (Finance 101's "compare to current price" step), an analyst might raise the target based on updated estimates while keeping the same Buy rating, simply reflecting a new, higher valuation output from an updated model, not a fundamentally new view on the company.

Sell-side vs. buy-side research — genuinely different audiences and incentives

Sell-side research (the work covered in this whole track) is published and distributed broadly to the bank's clients — its value is partly in being public, quotable, and widely read. Buy-side research (the internal work an asset manager or hedge fund's own analysts produce, connecting directly to the Asset Management track's investment-committee process) is proprietary and never published — its entire value lies in being a genuinely differentiated, non-consensus view the fund can act on before the broader market catches up, which is precisely why buy-side analysts often read sell-side research as one input among many, rather than as their primary source of original insight.

The real conflict of interest worth understanding honestly

A bank's equity research arm publishing on a company the bank's own investment banking division might want future advisory or capital-markets business from creates a genuine, structural incentive tension — research that's more favorable might help win banking business, while genuinely independent research (that occasionally recommends Sell on a client or potential-client company) can create real internal friction. Regulatory reforms in major markets have built real structural separations between research and banking (information barriers, independent research funding requirements in some jurisdictions) specifically to address this — worth knowing this tension exists and has a real regulatory response, not something to take at blind face value in either direction.

Worked example: how a rating and target actually move together over a real cycle

A stock starts at $40 with a $50 target and a Buy rating (25% implied upside). Over two quarters, the stock rallies to $48 on strong results, and the analyst raises estimates, pushing the target to $56 — upside is now ($56 − $48) ÷ $48 = 17%, likely still comfortably a Buy under a typical threshold. In a third quarter, growth decelerates meaningfully and the analyst cuts the target to $52 while the stock sits at $50 — upside now ($52 − $50) ÷ $50 = 4%, likely triggering an actual downgrade to Hold, since it's now below a typical Buy threshold — a genuine example of the rating following the fundamentals and the math, not just following the stock price.